We further investigated the immunogenicity of the T790M-5 and T790M-7 epitopes in 22 HLA-A2+ NSCLC patients harboring the EGFR gene mutations in exon 19 (delE746-A750) or exon 21 (L858R), who had been sensitive (n  =  8) or resistant (n  =  14) to the EGFR-TKI treatment at the blood sampling (Table 2). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.